DHA-PQP dispersible

Alfasigma

Product vision
  • 3-day cure, artemisinin-based combination therapy (dihydroartemisinin-piperaquine)
Dosing
  • Once-daily for 3 days

Efficacy
  • Efficacy in adults established. Pharmacokinetic bridging strategy to establish paediatric dose

Key features
  • Anticipated comparatively long post-treatment protection

Challenges
  • Potential cardiac monitoring restrictions
  • Confirmed piperaquine resistance in Greater Mekong Sub-region (GMS)
Status
  • Pharmacokinetic studies in children completed
  • Dossier under development for submission to EMA
Next milestone
  • Submission to EMA 

MMV Project Director
  • Adam Aspinall (ad interim)